NCPI
NIH Cloud PlatformInteroperability Effort
searchclose
YouYube

Study

arrow_backDatasets

NHLBI TOPMed: Best ADd-on Therapy Giving Effective Response (BADGER)

phs001728.v1.p1dbGapdbGap FHIR

Description

BADGER is a 56-week randomized, double-blind, three-treatment, three-period cross-over trial that will evaluate the differential improvement in control that is achieved following three separate treatment interventions in children whose asthma is not acceptably controlled on a low dose of ICS (per NAEPP guidelines). All participants will enter an 8-week run-in period during which time they will receive a dose of 1x ICS (fluticasone 200 μg/day). During this 8-week time period, running 2-week averages to establish the lack of acceptable asthma control will be calculated. Thus, a child could qualify for randomization at any time during this 8-week run-in period. This approach should maximize both patient safety and successful enrollment. Children will continue to receive 1x ICS during the entire treatment phase. During each period of the treatment phase, they also will receive one add-on therapy in the form of LABA, LTRA or additional 1x ICS. The order of the add-on therapy assignment will be determined by randomization into one of six treatment sequences (order determined randomly). Each treatment period will be 16 weeks in length; the initial 4 weeks of each period will be considered to be the washout period for the previous treatment. The primary outcome measures will be frequency of asthma exacerbations, asthma control days, and FEV1.

Summary

PlatformsBDC
Consent CodesDS-ASTHMA-IRB-COL
Focus / DiseasesAsthma
Study DesignProspective Longitudinal Cohort
Data TypesSNP/CNV Genotypes (NGS), WGS
Subjects50